Survivors’ plasma might prevent coronavirus infections

Do we already have a temporary COVID-19 vaccine?

Plasma from coronavirus survivors is already being used to treat COVID-19, thanks to the antibodies in survivors’ blood, although it’s too soon to say how effective this is.

But now, some researchers are also studying whether this therapy, known as convalescent plasma, can actually prevent coronavirus infections.

If so, it could mean that a COVID-19 vaccine — albeit one that provides only temporary immunity — is already within our grasp.

Plasma to Prevent Coronavirus

When the immune system encounters a virus for the first time, it produces antibodies, which alert it to attack the virus if it infects the body again in the future.

Most vaccines produce immunity by prompting the immune system to create antibodies to a virus before an infection ever takes hold. But vaccines can take a long time to develop — it’s possible that a COVID-19 vaccine won’t be ready for widespread distribution until mid-2021.

While an injection of antibody-rich blood plasma wouldn’t teach the immune system how to create its own coronavirus antibodies like a vaccine would, researchers suspect it could provide a person with similar immunity for about two to three months.

Studies of convalescent plasma therapy as a way to prevent coronavirus infections are now underway.

In April, a  team led by scientists at Johns Hopkins University launched a study involving 150 people at high risk of contracting COVID-19 (healthcare workers, first responders, etc.).

Each participant is receiving an injection of either plasma from a coronavirus survivor or placebo plasma collected before the COVID-19 pandemic began.

The researchers are looking to see whether the survivors’ plasma appears to prevent coronavirus infections, even temporarily — and if it does, they envision a future in which the plasma could be used to protect other vulnerable populations.

“They’re a paramedic, they’re a police officer, they’re a poultry industry worker, they’re a submarine naval officer,” researcher Shmuel Shoham told the Associated Press in June. “Can we blanket protect them?”

Alternatives to a COVID-19 Vaccine

Instead of directly injecting coronavirus survivors’ plasma into people, some researchers suggest creating concentrated immune globulin (IG) shots from survivors’ antibodies.

IGs are drugs that contain high concentrations of antibodies, and IG shots that provide temporary immunity to other illnesses, including hepatitis A and measles, already exist.

Plasma injections might prevent coronavirus infections until a vaccine is ready.

Unlike straight injections of coronavirus survivors’ plasma, an IG shot for COVID-19 would require some extra development, but proponents argue it’d be worth the time and money, as the shots would be easier to scale-up and have a longer shelf life than whole plasma.

Still, two California researchers hoping to develop IG shots for coronavirus recently told the Los Angeles Times that they’re having trouble securing funding for studies.

If research into IG shots doesn’t get going soon, plasma injections might be the most likely use of survivor’s antibodies to prevent coronavirus infections until a COVID-19 vaccine is ready.

We’d love to hear from you! If you have a comment about this article or if you have a tip for a future Freethink story, please email us at tips@freethink.com.

Related
Scientists have invented a method to break down “forever chemicals” in our drinking water
Researchers have discovered a way to eliminate “forever chemicals,” or PFAS, which usually take hundreds or thousands of years to break down.
When an antibiotic fails: MIT scientists are using AI to target “sleeper” bacteria
Most antibiotics target metabolically active bacteria, but AI can help efficiently screen compounds that are lethal to dormant microbes.
The threat of avian flu — and what we can do to stop it
Avian flu is infecting cows on US dairy farms, and now a person has caught it — but new research could help us avoid a bird flu pandemic.
What’s next for COVID-19 drugs?
Paxlovid may have underperformed in a new trial, but other promising COVID-19 drugs are being authorized or in the works.
New antiviral shortens COVID-19 by 1.5 days
People taking simnotrelvir, a new antiviral treatment for COVID-19, felt almost immediate symptom relief and got better 1.5 days faster.
Up Next
Reusable N95 Mask
Exit mobile version